| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jordi Tomas-Roig, Oliver Wirths, Gabriela Salinas-Riester, Ursula Havemann-Reineck. The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation In Vitro and Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination. CNS neuroscience & therapeutics. vol 22. issue 5. 2017-01-16. PMID:26842941. |
with the rationale that cb1 receptor is expressed in oligodendrocytes and marijuana consumption alters cns myelination, we study the effects of the cannabinoid agonist win55212.2 in (1) an in vitro model of oligodendrocyte differentiation and (2) the cuprizone model for demyelination. |
2017-01-16 |
2023-08-13 |
Not clear |
| Yuri P Springer, Roy Gerona, Erich Scheunemann, Sarah L Shafer, Thomas Lin, Samuel D Banister, Michael P Cooper, Louisa J Castrodale, Michael Levy, Jay C Butler, Joseph B McLaughli. Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016. MMWR. Morbidity and mortality weekly report. vol 65. issue 40. 2017-01-11. PMID:27736839. |
scs are a chemically diverse class of designer drugs that bind to the same cannabinoid receptors as tetrahydrocannabinol, the main psychoactive component of cannabis. |
2017-01-11 |
2023-08-13 |
Not clear |
| Phillip Gregoire, Michael Tau, David Robertso. Cannabinoid hyperemesis syndrome and the onset of a manic episode. BMJ case reports. vol 2016. 2017-01-09. PMID:27122104. |
cannabinoid hyperemesis syndrome is a rare, recently described, clinically diagnosed condition that is characterised by a chronic history of cannabis use, cyclic nausea and vomiting, symptomatic relief with hot water bathing, and resolution with cessation of use. |
2017-01-09 |
2023-08-13 |
Not clear |
| . Establishment of a New Drug Code for Marihuana Extract. Final rule. Federal register. vol 81. issue 240. 2017-01-09. PMID:28000787. |
to better track these materials and comply with treaty provisions, dea is creating a separate code number for marihuana extract with the following definition: "meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus cannabis, other than the separated resin (whether crude or purified) obtained from the plant." |
2017-01-09 |
2023-08-13 |
Not clear |
| Patrick J Ronan, Narin Wongngamnit, Thomas P Beresfor. Molecular Mechanisms of Cannabis Signaling in the Brain. Progress in molecular biology and translational science. vol 137. 2016-12-30. PMID:26810000. |
we are at crossroads for research on endocannabinoid function and therapeutics (including the use of exogenous treatments such as cannabis). |
2016-12-30 |
2023-08-13 |
Not clear |
| Patrick J Ronan, Narin Wongngamnit, Thomas P Beresfor. Molecular Mechanisms of Cannabis Signaling in the Brain. Progress in molecular biology and translational science. vol 137. 2016-12-30. PMID:26810000. |
with over 100 cannabinoid constituents, the majority of which have not been studied, there is much cannabis research yet to be done. |
2016-12-30 |
2023-08-13 |
Not clear |
| Patrick J Ronan, Narin Wongngamnit, Thomas P Beresfor. Molecular Mechanisms of Cannabis Signaling in the Brain. Progress in molecular biology and translational science. vol 137. 2016-12-30. PMID:26810000. |
with more states legalizing both the medicinal and recreational use of marijuana the rigorous scientific investigation into cannabinoid signaling is imperative. |
2016-12-30 |
2023-08-13 |
Not clear |
| Richard J Schrot, John R Hubbar. Cannabinoids: Medical implications. Annals of medicine. vol 48. issue 3. 2016-12-30. PMID:26912385. |
with elucidation of the chemical structures of tetrahydrocannabinol (thc) and cannabidiol (cbd) and with discovery of the human endocannabinoid system, the medical usefulness of cannabinoids has been more intensively explored. |
2016-12-30 |
2023-08-13 |
human |
| Richard J Schrot, John R Hubbar. Cannabinoids: Medical implications. Annals of medicine. vol 48. issue 3. 2016-12-30. PMID:26912385. |
while herbal cannabis has not met rigorous fda standards for medical approval, specific well-characterized cannabinoids have met those standards. |
2016-12-30 |
2023-08-13 |
human |
| Karl B Scheidweiler, Matthew N Newmeyer, Allan J Barnes, Marilyn A Huesti. Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. Journal of chromatography. A. vol 1453. 2016-12-29. PMID:27236483. |
identifying recent cannabis intake is confounded by prolonged cannabinoid excretion in chronic frequent cannabis users. |
2016-12-29 |
2023-08-13 |
Not clear |
| Karl B Scheidweiler, Matthew N Newmeyer, Allan J Barnes, Marilyn A Huesti. Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. Journal of chromatography. A. vol 1453. 2016-12-29. PMID:27236483. |
by simultaneously monitoring multiple cannabinoids and metabolites, identification of recent cannabis administration or discrimination between licit medicinal and illicit recreational cannabis use can be improved. |
2016-12-29 |
2023-08-13 |
Not clear |
| Joseph M Pierre, Michael Gandal, Maya So. Cannabis-induced psychosis associated with high potency "wax dabs". Schizophrenia research. vol 172. issue 1-3. 2016-12-27. PMID:26876313. |
although "dabbing" with cannabis wax is becoming increasingly popular in the us for both recreational and "medicinal" intentions, our cases raise serious concerns about its psychotic liability and highlight the importance of understanding this risk by physicians recommending cannabinoids for purported medicinal purposes. |
2016-12-27 |
2023-08-13 |
Not clear |
| Anne M Riederer, Sharan L Campleman, Robert G Carlson, Edward W Boyer, Alex F Manini, Paul M Wax, Jeffrey A Bren. Acute Poisonings from Synthetic Cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015. MMWR. Morbidity and mortality weekly report. vol 65. issue 27. 2016-12-23. PMID:27413997. |
studies of synthetic cannabinoids indicate higher cannabinoid receptor binding affinities, effects two to 100 times more potent than Δ(9)-tetrahydrocannabinol (the principal psychoactive constituent of cannabis), noncannabinoid receptor binding, and genotoxicity (4,5). |
2016-12-23 |
2023-08-13 |
Not clear |
| J Andrew Woods, Nicholas J D Wright, Jonathan Gee, Martin W Scobe. Cannabinoid Hyperemesis Syndrome: An Emerging Drug-Induced Disease. American journal of therapeutics. vol 23. issue 2. 2016-12-22. PMID:24413371. |
symptoms of cannabinoid hyperemesis resolve with cannabis cessation and recur when cannabis use is reinitiated, supporting an association between chronic use and cyclic vomiting. |
2016-12-22 |
2023-08-12 |
Not clear |
| Richard S McLachla. Marijuana: a time-honored but untested treatment for epilepsy. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. vol 42. issue 2. 2016-12-15. PMID:25715711. |
the biology of the endocannabinoid system in the brain provides a possible basis for a beneficial pharmacological effect of marijuana on seizures. |
2016-12-15 |
2023-08-13 |
Not clear |
| Maria Scherma, Christian Dessì, Anna Lisa Muntoni, Salvatore Lecca, Valentina Satta, Antonio Luchicchi, Marco Pistis, Leigh V Panlilio, Liana Fattore, Steven R Goldberg, Walter Fratta, Paola Fadd. Adolescent Δ(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 41. issue 5. 2016-12-14. PMID:26388146. |
these findings-that early, passive exposure to thc can produce lasting alterations of the reward system of the brain and subsequently increase cannabinoid self-administration in adulthood-suggest a mechanism by which adolescent cannabis exposure could increase the risk of subsequent cannabis dependence in humans. |
2016-12-14 |
2023-08-13 |
rat |
| Marvin Louis Roy Y Lu, Markus D Agit. Cannabinoid hyperemesis syndrome: Marijuana is both antiemetic and proemetic. Cleveland Clinic journal of medicine. vol 82. issue 7. 2016-12-13. PMID:26185942. |
cannabinoid hyperemesis syndrome: marijuana is both antiemetic and proemetic. |
2016-12-13 |
2023-08-13 |
Not clear |
| Marvin Louis Roy Y Lu, Markus D Agit. Cannabinoid hyperemesis syndrome: Marijuana is both antiemetic and proemetic. Cleveland Clinic journal of medicine. vol 82. issue 7. 2016-12-13. PMID:26185942. |
although marijuana is sometimes used to treat chemotherapy-induced nausea and vomiting, when used long-term it can have a paradoxical hyperemetic effect known as cannabinoid hyperemesis syndrome. |
2016-12-13 |
2023-08-13 |
Not clear |
| Raymond J M Niesink, Sander Rigter, Maarten W Koeter, Tibor M Brun. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction (Abingdon, England). vol 110. issue 12. 2016-12-13. PMID:26234170. |
in contrast with imported marijuana, nederwiet hardly contained any cannabidiol (cbd), a cannabinoid that is thought to offset some of the adverse effects of thc. |
2016-12-13 |
2023-08-13 |
Not clear |
| Raymond J M Niesink, Sander Rigter, Maarten W Koeter, Tibor M Brun. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction (Abingdon, England). vol 110. issue 12. 2016-12-13. PMID:26234170. |
this study investigates the further decrease or increase of cannabinoids in these cannabis products. |
2016-12-13 |
2023-08-13 |
Not clear |